Q-omics provides the consensus-scored SMIM27 profile across patient tissues and cancer cell-line models. SMIM27 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SMIM27 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, SMIM27 RNA expression shows 16,849 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KICH, and THYM as cancer lineages where SMIM27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM27 survival associations across molecular data types. SMIM27 RNA expression shows survival associations in the most cancer types (19), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM27 RNA expression–survival associations across cancer types. High SMIM27 expression shows unfavorable associations in ACC and UVM, but favorable associations in KIRP, CESC, BRCA and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SMIM27 RNA expression.
This table summarizes SMIM27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM27 shows lower tumor expression in KICH, LUAD, KIRC, LUSC and BRCA and higher tumor expression in LIHC. The KICH box plot shows higher SMIM27 RNA expression in normal versus tumor tissue (log2 FC = −0.871, t-test p < 0.001).
This table shows molecular features associated with SMIM27 in patient tissues and cancer cell lines. In patient samples, SMIM27 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC.
